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Tendons adapt to load under normal physiological conditions, however, under extreme loading 
conditions, such as those experienced by elite endurance athletes, incomplete adaptation may occur 
and cause injury. The prevalence of tendinopathies in elite endurance athletes is approximately 50%, 
thus variability exists in an athlete's tolerance to extreme loading.  A number of intrinsic and extrinsic 
factors contribute to modulating injury risk, some of which are modifiable and others, such as genetic 
variants, are non-modifiable. It was hypothesized that elite marathon runners would possess a genotype 
associated with enhanced tendon function, and thus protective against tendinopathy. Here, we 
compared the genotype frequencies of six genetic variants (COL1A1 rs1800012, VEGFA rs699947, TIMP2 
rs4789932, MMP3 rs591058, MMP3 rs650108, MMP3 rs679620), previously associated with 
tendinopathy, in elite (men <2 h 30 min, n = 109, women <3 h 00 min, n = 99) and sub-elite (men 2 h 30 
min-2 h 45 min, n = 189; women 3 h 00 min-3 h 15 min, n = 71) marathon runners with those of a non-
athletic control group (n = 564). Genotype associations with marathon personal best time in the athlete 
group were also investigated. All participants provided either a whole blood, saliva or buccal cell sample, 
from which DNA was isolated, and genotyped for all six variants using real-time PCR.  Genotype 
frequency differed between athletes and controls for TIMP2 rs4789932 (TT = 17%, CT = 51%, CC = 32% 
vs. TT = 22%, CT = 42%, CC = 36%, respectively; χ2 = 8.135, P = 0.017) only. However, there was no clear 
difference in allele frequencies between groups for TIMP2 rs4789932. MMP3 rs650108 genotype 
frequency differed between female elite and sub-elite athletes (χ2 = 11.913, P = 0.003) only and, as 
hypothesized, it was the “risk” A-allele that was ~10% less frequent in the elite, than sub-elite athletes. 
Following combination of all genotype data into a total genotype score, no differences in score between 
athletes and controls were observed (t = 2.93, P = 0.769). Similarly, no associations between total 
genotype score and marathon personal best time in male and female runners were observed (r ≤ 0.066, 
P ≥ 0.394). The results suggest elite marathon runners do not possess a genotype protective against 
tendinopathy, at least for the tendon-related genetic variants we investigated. 
